Screener
Zevra Therapeutics, Inc. ZVRA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | $46,642 | $71,608 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 6,074 | 5,579 |
| Impairment of intangible assets | — | 58,710 |
| Inventory obsolescence charge | 485 | 11,681 |
| Income tax expense | 7,617 | 3,381 |
| Depreciation and amortization expense | 732 | 3,300 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s stock-based comp?
- Zevra Therapeutics, Inc. (ZVRA) reported stock-based comp of $2.97M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Zevra Therapeutics, Inc.'s stock-based comp increased by 20.5% year-over-year, from $2.46M to $2.97M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s stock-based comp has grown at a 50.9% compound annual growth rate (CAGR), from $2.44M to $12.63M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Zevra Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude